Watchman vs. Blood Thinners: Alternatives for Patients with Nonvalvular Atrial Fibrillation

New implant technology designed to thwart stroke shows promise for patients with atrial fibrillation who cannot take anticoagulants. Here’s what potential recipients need to know.

7:00 AM

Author | Kevin Joy

Watchman Implant or Blood Thinners for Nonvalvular Atrial Fibrillation

Patients with nonvalvular atrial fibrillation (Afib), the most common type of abnormal heart rhythm, are at increased risk of stroke and may need a blood-thinning anticoagulant to reduce the risk. However, some patients who need blood thinners may not be able to take them because of a high risk of life-threatening bleeding.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

For such patients with nonvalvular atrial fibrillation who also are at high risk for severe bleeding complications, a quarter-sized device known as the Watchman might be a viable alternative. The tool blocks off a section of the heart commonly linked to blood clots, preventing any clots from escaping into the bloodstream.

"This is certainly something that can and should be considered in carefully evaluated, appropriate patients with nonvalvular Afib who need an anticoagulant but also are at high risk for severe bleeding complications," says Hakan Oral, M.D., a cardiologist at Michigan Medicine's Frankel Cardiovascular Center.

Available internationally since 2009, the Watchman has been approved since 2015 by the Food and Drug Administration. The Frankel center is one of the first facilities in the United States to use the device.

How the Watchman works

The lightweight, umbrella- or parachute-shaped device is inserted by catheter through a recipient's blood vessel accessed through the groin. It is designed to seal off the heart's left atrial appendage (a sacklike pouch within one of the organ's two upper chambers; the left atrial appendage is where Afib patients most often develop blood clots). A person's heart tissue will grow over the permanent implant in time.

The devices are available in several sizes to best fit a recipient's body.

Prior studies demonstrated that the Watchman was noninferior to the blood thinner warfarin, leading to FDA approval.  

But, as the FDA notes in a Watchman information guide, the device targets only one potential source of trouble. It cannot thwart other causes of stroke such as high blood pressure or narrowing of blood vessels to the brain.

Eligible candidates

The Watchman isn't meant to be a universal alternative to anticoagulants. Only carefully chosen patients should receive it, Oral says. "If a patient has a high risk of bleeding while on blood thinners, then it is a very good option."

SEE ALSO: Clearing Up Confusion About Blood-Thinning Meds

Still, patients must be able to tolerate warfarin short term to qualify. A patient must also be at an increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores — numerical scales used to evaluate stroke risk in Afib patients.

A potential recipient will undergo a transesophageal echocardiogram (TEE) to ensure no existing clots are present and to determine whether the appendage is compatible with one of the available device sizes and shapes. Clots, if detected, will need to be treated with blood thinners before proceeding.

The Centers for Medicare and Medicaid Services announced in February 2016 that the Watchman will be covered, as long as patients meet specific criteria.

Living with the Watchman

Conducted under general anesthesia, the minimally invasive procedure doesn't typically involve a hospital stay of more than a day. Patients should be able to return to normal activities shortly after the procedure.

Extended follow-up, though, is involved. A recipient can expect subsequent TEEs at 45 days and 12 months after surgery to ensure that the Watchman is working properly and the left atrial appendage remains closed.

Patients also need to continue a warfarin regimen for 45 days.

"After a successful implant confirmed at 45 days with a TEE, the patient is taken off warfarin and put on a different type of blood thinner known as Plavix, along with aspirin, for another four and one-half months," Oral says. "The patient is then maintained on aspirin for life."

Like any other procedure, Oral says, the Watchman device has its own risks. "Therefore, patients must be carefully chosen."

Want to know which option is right for you? Call the Frankel Cardiovascular Center at 888-287-1082 for more information or to make an appointment.


More Articles About:

Heart Health Atrial fibrillation (Afib) Frankel Cardiovascular Center Emerging Technologies Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Well-Being at Michigan Medicine with Dr. Elizabeth Harry
Well-Being at Michigan Medicine

The Power of Mattering

What does it take to create a culture where people can truly thrive? In this episode, Dr. Elizabeth Harry welcomes Dr. Robert Ernst, Chief Health Officer and Associate Vice President for Health and Wellness at the University of Michigan, about building well-being into systems, policies and everyday experiences. They explore purpose-driven leadership, belonging, mental health and why helping people feel they matter can strengthen entire communities.
Health Lab

AI chatbots spark mental health concerns, including psychosis risk

Artificial intelligence-driven AI chatbots have been linked to cases of suicide, delusions, psychosis and mental health issues. Three experts from Michigan Medicine explain what’s known and how to respond.
grandma with baby in arms smiling
Health Lab

Treating a rare coronary artery aneurysm without open heart surgery

Cardiologists at University of Michigan Health prevented the rupture of an aneurysm in a woman’s heart and used a minimally invasive solution to avoid open heart surgery. 
mother with four kids smiling
Health Lab

A heart attack 9 days after giving birth: Mother of 4 shares her SCAD experience

A mother of four shares journey with a rare heart attack just days after birth called Spontaneous Coronary Artery Dissection, a leading cause of heart attacks in women under 50.
Nurse or home caregiver and senior woman holding hands at home
Health Lab

Severe strokes linked to 5 times higher dementia risk

As stroke severity increases, the risk of progressive cognitive decline and dementia substantially rises, according to a national study led by Michigan Medicine researchers.
A woman stands in a plaid sweater over a red shirt with a cross necklace on the left. On the right, a woman in a hospital gown poses for a photo by the window with two people.
Health Lab

Fighting rejection antibodies to make heart transplant possible

A woman who spent more than a decade with life-threatening heart rhythms received a transplant despite having high levels of antibodies that reject donor organs.